TRAP-Paclitaxel for Equine Eyelid Squamous Cell Carcinoma
Principle Investigator
Description
This is a dose-escalation clinical trial to determine the effectiveness of a novel chemotherapeutic drug, TRAP-Paclitaxel, for the treatment of equine squamous cell carcinoma (SCC). The study will consist of an initial visit with biopsy, and 1-3 injections of TRAP-Paclitaxel at a minimum of 6 weeks apart. Horses will return for recheck appointments for up to 1 year past their last injection.
Testing Requirements
– Full ophthalmic exam (each appointment)
– High-frequency ultrasound of tumor (each appointment)
– Histopathology of tumor (first appointment, last appointment)
– CBC/Chem (Baseline and 2 weeks after first injection)
– NSAID panels (periodically during treatment)
– Blood samples for pharmacokinetics (baseline, 3, 6, and 24 hours after first injection, and 2 and 6 weeks after first injection)
Enrollment Start
10/01/2025
Enrollment Finish
10/01/2026
Eligibility
Horses must have squamous cell carcinoma of the eyelid confirmed via biopsy/histopathology with a longest diameter of at least 10 mm. Owners must be willing to bring horses to NCSU for recheck appointments at 2-6 week intervals for up to 3 injections, and then at 4-6 month intervals until 1 year past the last injection. Owners must be willing to send photographs of the eye to researchers on a weekly to biweekly basis for 6 weeks after each injection.
Flyer
Contact
Dr. Annie Oh aoh@ncsu.edu
- Categories:
